Messengers from the microbiota.

The article discusses gut microbiota and how it acts as a critical determinant for immunotherapy responses. It cites a research by L. F. Mager published in this issue, which reveals how inosine produced by specific gut bacteria improves immune checkpoint inhibitor (ICI) efficacy in numerous mouse models. It mentions the need to understand the biosynthetic metabolite redundancy among bacterial species.